Search Result

Results for "

polycystic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) CDK (5) CFTR (1) Cytochrome P450 (1) Endogenous Metabolite (3) Estrogen Receptor/ERR (1) G protein-coupled Bile Acid Receptor 1 (1) Glucosylceramide Synthase (GCS) (3) GSK-3 (1) Isotope-Labeled Compounds (1) MicroRNA (1) Vasopressin Receptor (1)
By Research Areas:	Cancer (3) Endocrinology (2) Inflammation/Immunology (1) Metabolic Disease (13) Neurological Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14179

PPQ-102 3 Publications Verification CFTR Inhibitor	CFTR	Others
PPQ-102 (CFTR Inhibitor) is a reversible CFTR inhibitor that completely inhibits CFTR chloride currents (IC₅₀ ~90 nM). PPQ-102 is not affected by membrane potential-dependent cell allocation or blocking efficiency (uncharged at physiological pH) and effectively prevents cyst enlargement in polycystic kidney disease .

HY-145694

CDK5-IN-3	CDK	Metabolic Disease
CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC₅₀s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) .

HY-150076

BLU2864	Others	Metabolic Disease Cancer
BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC₅₀=0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research .

HY-139290

RGLS4326 RG4326	MicroRNA	Metabolic Disease Cancer
RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 inhibits miR-17 function in HeLa cells with an EC₅₀ value of 28.3 nM .

HY-146272

Vasopressin V2 receptor antagonist 1	Vasopressin Receptor	Metabolic Disease
Vasopressin V2 receptor antagonist 1 (Compound 4g) is a vasopressin V₂ receptor (V₂R) antagonist with a K_i of 3.8 nM. Vasopressin V2 receptor antagonist 1 can be used for autosomal dominant polycystic kidney disease (ADPKD) research .

HY-151878

CDK7-IN-20	CDK GSK-3	Metabolic Disease
CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC₅₀ value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research .

HY-153911

H2-Gamendazole	Others	Endocrinology
H2-Gamendazole is a derivative of Lonidamine that reduces cyst formation in polycystic kidney disease and is used in autosomal dominant polycystic kidney disease research .

HY-149770

CYP4A11/CYP4F2-IN-2	Cytochrome P450	Metabolic Disease
CYP4A11/CYP4F2-IN-2 (compound 15) is an orally available inhibitor of CYP4A11/4F2 with IC₅₀s of 120 nM and 220 nM, respectively. CYP4A11/CYP4F2-IN-2 inhibits 20-HETE production in rat kidney and has potential inhibitory effects on diabetic nephropathy and autosomal dominant polycystic kidney disease .

HY-111534

SBI-115 Maximum Cited Publications 14 Publications Verification	G protein-coupled Bile Acid Receptor 1	Others
SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5 .

HY-16743

Ibiglustat 2 Publications Verification Venglustat; SAR402671; GZ402671	Glucosylceramide Synthase (GCS)	Metabolic Disease
Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .

HY-16743B

Ibiglustat succinate 2 Publications Verification Venglustat succinate; SAR402671 succinate; GZ402671 succinate	Glucosylceramide Synthase (GCS)	Neurological Disease
Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .

HY-N9410S

Lysophosphatidylcholine 18:2-d9 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC-d₉	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Lysophosphatidylcholine 18:2-d₉ is deuterium labeled Lysophosphatidylcholine 18:2. Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary

HY-16743A

Ibiglustat (L-Malic acid) 2 Publications Verification Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid)	Glucosylceramide Synthase (GCS)	Metabolic Disease
Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .

HY-N3021

D-chiro-Inositol	Endogenous Metabolite	Metabolic Disease
D-chiro-Inositol is an epimer of myo-inositol found in certain mammalian glycosylphosphatidylinositol protein anchors and inositol phosphoglycans possessing insulin-like bioactivity. D-chiro-Inositol is used clinically for the treatment of polycystic ovary syndrome (PCOS) and diabetes mellitus, which can reduce hyperglycemia and ameliorate insulin resistance .

HY-144425

BSc5367	Others	Inflammation/Immunology
BSc5367 is a potent Nek1 inhibitor with an IC₅₀ of 11.5 nM. NIMA-related protein kinase Nek1 is crucially involved in cell cycle regulation, DNA repair and microtubule regulation and dysfunctions of Nek1 play key roles in amyotrophic lateral sclerosis (ALS), polycystic kidney disease (PKD) and several types of radiotherapy resistant cancer .

HY-N9410

Lysophosphatidylcholine 18:2 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC	Endogenous Metabolite	Metabolic Disease
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment .

HY-B0463

Clomiphene citrate 4 Publications Verification Clomifene citrate	Estrogen Receptor/ERR	Neurological Disease Endocrinology Cancer
Clomiphene citrate (Clomifene citrate) is an orally active estrogen-receptor modulator. Clomiphene citrate has anti-cancer actixity, induces perturbations during meiotic maturation and cytogenetic abnormalities and ameliorates in managing psychiatric and cognitive impairment .

HY-139725

CDK5-IN-1

CDK Metabolic Disease

CDK5-IN-1, a potent CDK5 inhibitor, is against CDK5 activity less than 10 nM. CDK5-IN-1 is used for kidney diseases research .
HY-145693

CDK5-IN-2

CDK Others

CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor with IC₅₀s of 0.2 and 23 for CDK5/p25 and CDK2/CycA, respectively .

CDK5-IN-1	CDK	Metabolic Disease
CDK5-IN-1, a potent CDK5 inhibitor, is against CDK5 activity less than 10 nM. CDK5-IN-1 is used for kidney diseases research .

CDK5-IN-2	CDK	Others
CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor with IC₅₀s of 0.2 and 23 for CDK5/p25 and CDK2/CycA, respectively .

HY-144117

GFB-12811	CDK	Metabolic Disease
GFB-12811 is a high selective and orally active CDK5 inhibitor with an IC₅₀ of 2.3 nM. GFB-12811 is highly selective over the other tested kinases (CDK1/2/6/7/9) .

HY-W021265

Cyclohexane-1,2,3,4,5,6-hexaol Cyclohexane-1,2,3,4,5,6-hexol	Biochemical Assay Reagents	Others
Cyclohexane-1,2,3,4,5,6-hexaol, also known as inositol or inositol, is a cyclic sugar alcohol consisting of a six-carbon ring with six hydroxyl groups. This compound is important for its biological activity and is widely distributed in nature, especially in plant and animal tissues. It plays a role in various physiological processes such as signal transduction, osmoregulation and lipid metabolism. In addition, Cyclohexane-1,2,3,4,5,6-hexaol has potential investigational effects, including improving conditions related to insulin resistance, polycystic ovary syndrome, and mental health conditions. It can also be used as a supplement in animal feed and human nutritional products.

Cyclohexane-1,2,3,4,5,6-hexaol Cyclohexane-1,2,3,4,5,6-hexol	Biochemical Assay Reagents
Cyclohexane-1,2,3,4,5,6-hexaol, also known as inositol or inositol, is a cyclic sugar alcohol consisting of a six-carbon ring with six hydroxyl groups. This compound is important for its biological activity and is widely distributed in nature, especially in plant and animal tissues. It plays a role in various physiological processes such as signal transduction, osmoregulation and lipid metabolism. In addition, Cyclohexane-1,2,3,4,5,6-hexaol has potential investigational effects, including improving conditions related to insulin resistance, polycystic ovary syndrome, and mental health conditions. It can also be used as a supplement in animal feed and human nutritional products.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3021

D-chiro-Inositol	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
D-chiro-Inositol is an epimer of myo-inositol found in certain mammalian glycosylphosphatidylinositol protein anchors and inositol phosphoglycans possessing insulin-like bioactivity. D-chiro-Inositol is used clinically for the treatment of polycystic ovary syndrome (PCOS) and diabetes mellitus, which can reduce hyperglycemia and ameliorate insulin resistance .

HY-N9410

Lysophosphatidylcholine 18:2 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC	Infection Natural Products Classification of Application Fields Source classification Disease markers Metabolic Disease Endocrine diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment .

Cat. No.	Product Name	Chemical Structure

HY-N9410S

Lysophosphatidylcholine 18:2-d9
Lysophosphatidylcholine 18:2-d₉ is deuterium labeled Lysophosphatidylcholine 18:2. Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

polycystic

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Natural
Products